Aurinia Pharmaceuticals Inc. Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement
Aurinia Pharmaceuticals Inc. (AUPH) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement of CAD 8.14 for the 12-month period ending 2019-12-31, per its 40-F filed 2020-03-05.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement · last filed 2020-03-05
CAD
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement 12 month |
|---|---|---|
| 2019-12-31 | 8.14 CAD 40-F · filed 2020-03-05 | |
| 2019-11-19 | 7.59K CAD 40-F · filed 2020-03-05 | |
| 2018-12-31 | 6.54 CAD 40-F · filed 2020-03-05 | |
| 2017-12-31 | 5.44 CAD 40-F · filed 2019-03-19 | |
| 2015-12-31 | 3.43 CAD 40-F · filed 2018-03-15 |
USD
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement |
|---|---|
| 2019-11-19 | $5.73K 40-F · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |